Subscribe
Sign in
Subscribe
Sign in
GlobalData
GlobalData

Pharma

Pfizer and BioNTech’s final Phase III COVID-19 vaccine analysis could decrease by 10 points from interim 90% data; vaccine could require testing to screen prior infection but rationale still theoretical

With Pfizer and BioNTech announcing that a Phase III trial investigating the BNT162b2 vaccine to be 90% effective in preventing symptomatic COVID-19 in participants without evidence of prior infection; Reynald Castañeda, Pharma Writer for the Investigative News team at GlobalData, offers his view:   “The final Phase III efficacy analysis of Pfizer/BioNTech’s COVID-19 vaccine BNT162b2 […]
Read more

Key players in breast cancer space engage effectively with Japanese patients through unbranded digital strategies, says GlobalData

In Japan, the breast cancer treatment landscape consists of various systemic therapies including chemotherapy, hormonal therapy, targeted therapy and immunotherapy. Key players in this space provide competitive digital support through branded and unbranded channels. However, patient engagement through unbranded channels to create disease awareness has been more prominent, observes GlobalData, a leading data and analytics […]
Read more

Pharma was forced to shuffle technology investment priorities due to COVID-19

COVID-19 has been a wake-up call for pharma companies to rethink their operations and customer access. Embracing digital transformation will have an important role to play in ensuring that the industry overcomes existing and long-term business challenges, seizes opportunities and continues to thrive in challenging business landscape, says GlobalData, a leading data and analytics company. […]
Read more

While Pfizer and BioNTech’s ‘90% efficacy’ data raises expectations for mRNA vaccines, it will take many more months for key questions to be answered, says GlobalData

Following the news that Pfizer and BioNTech have announced their COVID-19 vaccine is more than 90% effective in first interim data readout; Philipp Rosenbaum, PhD, Senior Infectious Diseases Analyst at GlobalData, a leading data and analytics company, offers his view: “Experts initially assumed that first iterations of a COVID-19 vaccine would show efficacies not much […]
Read more

Current global contract manufacturing will not keep up with global COVID-19 vaccine demand

A significant proportion of vaccine developers are smaller companies that lack the capacity and funds to manufacture their vaccines in-house. However, there is also simply not enough contract manufacturing capacity worldwide to cope with commercial COVID-19 vaccine demand, says GlobalData, a leading data and analytics company. Adam Bradbury, PharmSource Analyst at GlobalData, comments: “According to GlobalData’s Service Provider Database, there are 195 contract facilities at 123 companies offering vaccine active pharmaceutical ingredient (API) manufacture. It is difficult to […]
Read more

While Pfizer and BioNTech’s ‘90% efficacy’ data raises expectations for mRNA vaccines, it will take many more months for key questions to be answered

Following the news that Pfizer and BioNTech have announced their COVID-19 vaccine is more than 90% effective in first interim data readout; Philipp Rosenbaum, PhD, Senior Infectious Diseases Analyst at GlobalData, a leading data and analytics company, offers his view: “Experts initially assumed that first iterations of a COVID-19 vaccine would show efficacies not much better than common seasonal influenza vaccines, which are usually only 40–60% effective. At a reported 90%, Pfizer and BioNTech’s […]
Read more

EU Horizon 2020 research and innovation program invested almost €6M ($7.1M) for COVID-19

In response to the COVID-19 pandemic, Horizon 2020 (H2020), the EU’s biggest research and innovation program, invested almost €6M ($7.1M) for COVID-19 related research and drug development in April 2020. This demonstrates how granting agencies have reacted quickly to prioritizing COVID-19 research, says GlobalData, a leading data and analytics company. Keshalini Sabaratnam, Pharma Analyst at GlobalData, comments: “All […]
Read more

Lack of skills and talents poses the biggest challenge to digital transformation in pharmaceutical industry

COVID-19 is set to be a major catalyst for the pharmaceutical industry. The rush to adapt to new social distancing and lockdown norms has led to a hurried digital transformation, leaving many organizations struggling to bridge the digital skills gap, says GlobalData, a leading data and analytics company. GlobalData’s latest report, Digital Transformation and Emerging Technology […]
Read more

FDA likely to approve Biogen’s Aducanumab after its review

Following the release of FDA documents today noting support for the safety and efficacy of Biogen’s treatment for Alzheimer’s Disease (AD), aducanumab, it is looking very likely that the drug will become the first new AD therapy to be approved in 17 years. If it is approved, the drug could be in the market by […]
Read more

COVID-19 is driving more supplier redundancy

Contract development and manufacturing organizations (CDMOs) are busier than ever, and their work will increase as the pandemic prompts pharma companies to increase redundancy in the supply chain, says GlobalData, a leading data and analytics company. Peter Shapiro, PharmSource Senior Director of Drugs and Business Fundamentals at GlobalData, comments: “Pharma companies may try to reduce […]
Read more

Precarious future of Affordable Care Act leaves US contraceptive devices market at risk of contraction

Trump and Biden have sharply contrasting policies on female patient accessibility to reproductive healthcare. Trump has repeatedly expressed his mandate to overturn the Affordable Care Act (ACA), which currently covers female contraception to the list of preventative services without patient co-payment, unless an employer objects on religious or moral grounds. The reduced accessibility of contraceptives […]
Read more

COVID-19 caused Fujifilm to boost infectious disease manufacturing contract service deals in 2020

Fujifilm Diosynth Biotechnologies USA Inc., a contract development and manufacturing organization (CDMO), has shown a 200% increase in all deal volume for infectious disease drugs over the last year, says GlobalData, a leading data and analytics company. Sharon Cartic, Associate Director Research and Analysis at GlobalData, comments: “Fujifilm Diosynth Biotechnologies has manufacturing contract service agreements in […]
Read more

Gastric and gastroesophageal adenocarcinoma market set to reach $3.9bn by 2029

The gastric and gastroesophageal adenocarcinoma (G/GEJAC) market is expected to grow from $1.6bn in 2019 to $3.9bn in 2029 across the eight major markets (8MM*) at a moderate compound annual growth rate (CAGR) of 9.3%, according to GlobalData, a leading data and analytics company. GlobalData’s latest report, ‘Gastric and Gastroesophageal Junction Adenocarcinoma Global Drug Forecast and […]
Read more

Long HCC pipeline marks change for previously stagnant market

Despite the high unmet needs within hepatocellular carcinoma (HCC), the market was stagnant from 2007 until 2018, when the FDA approved Eisai’s Lenvima (lenvatinib) in first-line advanced HCC. The current landscape has seen a rapid change. The needs in the HCC space are likely to be met in the near future, as many new therapies […]
Read more
1 … 77 78 79 80 81 … 110